S&P 500   4,513.04
DOW   34,022.04
QQQ   387.12
S&P 500   4,513.04
DOW   34,022.04
QQQ   387.12
S&P 500   4,513.04
DOW   34,022.04
QQQ   387.12
S&P 500   4,513.04
DOW   34,022.04
QQQ   387.12

Lantheus Stock Forecast, Price & News

-0.66 (-2.46%)
(As of 12/1/2021 12:00 AM ET)
Today's Range
50-Day Range
52-Week Range
412,534 shs
Average Volume
554,674 shs
Market Capitalization
$1.77 billion
P/E Ratio
Dividend Yield
30 days | 90 days | 365 days | Advanced Chart
Receive LNTH News and Ratings via Email

Sign-up to receive the latest news and ratings for Lantheus and its competitors with MarketBeat's FREE daily newsletter.

Lantheus logo

About Lantheus

Lantheus Holdings, Inc. engages in the provision of diagnostic imaging and nuclear medicine products. The firm develops products that help healthcare professionals in patient management and outcomes, and assist clinicians with the detection of cardiovascular disease. It operates through the U.S. and International geographical segments. The U.S. segment produces and markets products, radiopharmacies, PMFs, integrated delivery networks, hospitals, clinics, and group practices throughout the United States. The International segment operations offers direct distribution in Canada and Puerto Rico; third-party distribution in Europe, Canada, Australia, Asia-Pacific, and Latin America; and EXINI business in Sweden. The company was founded in 1956 and is headquartered in North Billerica, MA.


Lantheus (NASDAQ:LNTH) Updates Q4 2021 Earnings Guidance
November 25, 2021 |  americanbankingnews.com
Lantheus (NASDAQ:LNTH) Updates FY 2021 Earnings Guidance
November 25, 2021 |  americanbankingnews.com
Lantheus (NASDAQ:LNTH) Releases FY 2021 Earnings Guidance
November 11, 2021 |  americanbankingnews.com
See More Headlines

Industry, Sector and Symbol

Diagnostic substances
Current Symbol
Year Founded

Sales & Book Value

Annual Sales
$339.41 million
Cash Flow
$0.85 per share
Book Value
$7.69 per share


Net Income
$-13.47 million
Pretax Margin




Free Float
Market Cap
$1.77 billion

Company Calendar

Last Earnings
Fiscal Year End
Next Earnings (Estimated)


Overall MarketRank

2.00 out of 5 stars

Medical Sector

615th out of 1,392 stocks

Diagnostic Substances Industry

7th out of 25 stocks

Analyst Opinion: 1.3Community Rank: 4.4Dividend Strength: 0.0Insider Behavior: 2.5Valuation: 1.9 5 -4 -3 -2 -1 -

Lantheus (NASDAQ:LNTH) Frequently Asked Questions

Is Lantheus a buy right now?

2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Lantheus in the last twelve months. There are currently 1 hold rating and 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Lantheus stock.
View analyst ratings for Lantheus
or view top-rated stocks.

How has Lantheus' stock been impacted by Coronavirus (COVID-19)?

Lantheus' stock was trading at $13.62 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, LNTH shares have increased by 91.8% and is now trading at $26.12.
View which stocks have been most impacted by COVID-19

Are investors shorting Lantheus?

Lantheus saw a decrease in short interest in the month of November. As of November 15th, there was short interest totaling 1,820,000 shares, a decrease of 28.9% from the October 31st total of 2,560,000 shares. Based on an average trading volume of 382,700 shares, the days-to-cover ratio is currently 4.8 days. Approximately 2.8% of the shares of the stock are short sold.
View Lantheus' Short Interest

When is Lantheus' next earnings date?

Lantheus is scheduled to release its next quarterly earnings announcement on Thursday, February 24th 2022.
View our earnings forecast for Lantheus

How were Lantheus' earnings last quarter?

Lantheus Holdings, Inc. (NASDAQ:LNTH) issued its quarterly earnings data on Thursday, November, 4th. The medical equipment provider reported $0.08 EPS for the quarter, beating the Thomson Reuters' consensus estimate of $0.06 by $0.02. The medical equipment provider had revenue of $102.10 million for the quarter, compared to analysts' expectations of $97.13 million. Lantheus had a negative net margin of 8.84% and a positive trailing twelve-month return on equity of 4.17%. The firm's revenue for the quarter was up 15.4% on a year-over-year basis. During the same quarter in the prior year, the company posted $0.04 EPS.
View Lantheus' earnings history

What guidance has Lantheus issued on next quarter's earnings?

Lantheus updated its FY 2021 earnings guidance on Thursday, November, 25th. The company provided earnings per share guidance of $0.400-$0.430 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $0.390. The company issued revenue guidance of $405 million-$410 million, compared to the consensus revenue estimate of $396.70 million.

What price target have analysts set for LNTH?

2 brokerages have issued 12 month price objectives for Lantheus' shares. Their forecasts range from $20.00 to $34.00. On average, they expect Lantheus' stock price to reach $27.00 in the next year. This suggests a possible upside of 3.4% from the stock's current price.
View analysts' price targets for Lantheus
or view top-rated stocks among Wall Street analysts.

Who are Lantheus' key executives?

Lantheus' management team includes the following people:
  • Mary Anne Heino, President, Chief Executive Officer & Director (LinkedIn Profile)
  • Robert J. Marshall, Chief Financial Officer & Treasurer
  • Simon Robinson, Senior VP-Research & Pharmaceutical Development
  • Iryna Teslenko, Vice President-Clinical Development
  • Bela S. Denes, Vice President-Medical Affairs

What is Mary Anne Heino's approval rating as Lantheus' CEO?

4 employees have rated Lantheus CEO Mary Anne Heino on Glassdoor.com. Mary Anne Heino has an approval rating of 51% among Lantheus' employees. This puts Mary Anne Heino in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Lantheus own?

When did Lantheus IPO?

(LNTH) raised $75 million in an IPO on Thursday, June 25th 2015. The company issued 7,900,000 shares at $8.50-$10.50 per share. Citigroup, Jefferies, RBC Capital Markets and Wells Fargo Securities served as the underwriters for the IPO and Baird was co-manager.

What is Lantheus' stock symbol?

Lantheus trades on the NASDAQ under the ticker symbol "LNTH."

Who are Lantheus' major shareholders?

Lantheus' stock is owned by many different retail and institutional investors. Top institutional investors include BlackRock Inc. (15.56%), Wellington Management Group LLP (7.00%), Thrivent Financial for Lutherans (4.40%), William Blair Investment Management LLC (3.89%), Artisan Partners Limited Partnership (3.19%) and Dimensional Fund Advisors LP (2.50%). Company insiders that own Lantheus stock include Andrea Sabens, Etienne Montagut, Heinz Christoph Maeusli, John J Bolla, Julie Mchugh, Mary Anne Heino, Michael P Duffy, Michael P Duffy, Paul Blanchfield, Robert J Jr Marshall and Sam R Leno.
View institutional ownership trends for Lantheus

Which institutional investors are selling Lantheus stock?

LNTH stock was sold by a variety of institutional investors in the last quarter, including Wellington Management Group LLP, Russell Investments Group Ltd., BlackRock Inc., Pura Vida Investments LLC, Peregrine Capital Management LLC, Boston Partners, MESIROW FINANCIAL INVESTMENT MANAGEMENT Equity & Fixed Income, and Tamarack Advisers LP. Company insiders that have sold Lantheus company stock in the last year include Andrea Sabens, Etienne Montagut, John J Bolla, Mary Anne Heino, Michael P Duffy, Paul Blanchfield, Robert J Jr Marshall, and Sam R Leno.
View insider buying and selling activity for Lantheus
or view top insider-selling stocks.

Which institutional investors are buying Lantheus stock?

LNTH stock was purchased by a variety of institutional investors in the last quarter, including William Blair Investment Management LLC, Polar Asset Management Partners Inc., Thrivent Financial for Lutherans, Fisher Asset Management LLC, Arrowstreet Capital Limited Partnership, The Manufacturers Life Insurance Company , Next Century Growth Investors LLC, and Royal Bank of Canada.
View insider buying and selling activity for Lantheus
or or view top insider-buying stocks.

How do I buy shares of Lantheus?

Shares of LNTH can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Lantheus' stock price today?

One share of LNTH stock can currently be purchased for approximately $26.12.

How much money does Lantheus make?

Lantheus has a market capitalization of $1.77 billion and generates $339.41 million in revenue each year. The medical equipment provider earns $-13.47 million in net income (profit) each year or ($0.51) on an earnings per share basis.

How many employees does Lantheus have?

Lantheus employs 595 workers across the globe.

What is Lantheus' official website?

The official website for Lantheus is www.lantheus.com.

Where are Lantheus' headquarters?

Lantheus is headquartered at 331 TREBLE COVE ROAD, NORTH BILLERICA MA, 01862.

How can I contact Lantheus?

Lantheus' mailing address is 331 TREBLE COVE ROAD, NORTH BILLERICA MA, 01862. The medical equipment provider can be reached via phone at (978) 671-8001, via email at [email protected], or via fax at 978-671-8860.

This page was last updated on 12/2/2021 by MarketBeat.com Staff


Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.